A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas

• Published in: European journal of cancer (1990) Vol. 208; p. 114129
• Main Authors: Bongiovanni, Alberto, Liverani, Chiara, Foca, Flavia, Bergamo, Francesca, Leo, Silvana, Pusceddu, Sara, Gelsomino, Fabio, Brizzi, Maria Pia, Di Meglio, Giovanni, Spada, Francesca, Tamberi, Stefano, Lolli, Ivan, Cives, Mauro, Marconcini, Riccardo, Pucci, Francesca, Berardi, Rossana, Antonuzzo, Lorenzo, Badalamenti, Giuseppe, Santini, Daniele, Recine, Federica, Vanni, Silvia, Tebaldi, Michela, Severi, Stefano, Rudnas, Britt, Nanni, Oriana, Ranallo, Nicoletta, Crudi, Laura, Calabrò, Luana, Ibrahim, Toni
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.09.2024
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Camptothecin - adverse effects; Camptothecin - analogs & derivatives; Camptothecin - therapeutic use; Captem; Carcinoma, Neuroendocrine - blood; Carcinoma, Neuroendocrine - drug therapy; Carcinoma, Neuroendocrine - mortality; Carcinoma, Neuroendocrine - pathology; Circulating miRNA; Etoposide - administration & dosage; Etoposide - adverse effects; Etoposide - therapeutic use; Female; Fluorouracil - adverse effects; Fluorouracil - therapeutic use; Folfiri; Humans; Leucovorin - adverse effects; Leucovorin - therapeutic use; Male; Middle Aged; Neuroendocrine carcinomas (NECs); Phase II trial; Progression-Free Survival; Temozolomide - adverse effects; Temozolomide - therapeutic use; Captem; Circulating miRNA; Neuroendocrine carcinomas (NECs); Folfiri; Phase II trial

Neuroendocrine Carcinomas (NECs) prognosis is poor.No standard second-line therapy is currently recognized after failure of platinum-based first-line treatment. FOLFIRI and CAPTEM regimens have shown promising activity in preliminary studies. We aimed to evaluate these regimens in metastatic NEC pat...